-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604.O1.6 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Strategies to Overcome Therapy Resistance in Myeloid Malignancies

Symposia: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Translational Research, Combination therapy, Diseases, Therapies, Myeloid Malignancies
Sunday, December 10, 2023: 9:30 AM-11:00 AM
Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)
Moderators:
Courtney L Jones, PhD, Cincinnati Children's Hospital Medical Center and Nicole R. Grieselhuber, MD, PhD, The Ohio State University Comprehensive Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
Development of therapy resistance remains a major hurdle in the treatment of myeloid malignancies. In this session approaches to overcome therapy resistance to agents including chemotherapy, hypomethylating agents, and venetoclax will be presented.
9:30 AM

Camille Vaganay1*, Frank Ling1*, Lois M. Kelly2*, Duong Ho Nhat2*, Antoine Forget, Ph.D.3*, Paul-Arthur Meslin1*, Hélène Pasquer, M.D.4*, Rathana Kim, Pharm.D.5*, Marie Passet, Pharm.D. / Ph.D.6*, Sofiane Fodil, M.D.7*, Tony Huynh, MD8*, Angela H Su9*, Christopher F Bassil, Ph.D.10*, Matthieu Duchmann, M.D. / Ph.D.11*, Gabriela Alexe, PhD12*, Gael Fortin13*, Carine Legrand, Ph.D.2*, Khansa Saadallah14*, Christopher Delaney15*, Kim Pacchiardi16*, Anja Kocijancic2*, Lisa Aziez17*, Nina Fenouille, Ph.D.1*, Marie Sebert, MD, PhD18*, Lionel Ades, MD, PhD19, Emmanuel Raffoux, M.D.20*, Emmanuelle Clappier, Pharm.D., Ph.D.21*, Lina Benajiba, MD, PhD16, Kimberly Stegmaier, MD9, Kris C. Wood, Ph.D.22*, Raphael Itzykson, M.D. / Ph.D.23, Camille Lobry, Ph.D.16* and Alexandre Puissant, Ph.D.24

1St Louis Hospital, INSERM U944, Paris, FRA
2St Louis Hospital, INSERM U944, PARIS, France
3Department of Cellular and Molecular Pharmacology (UCSF), Nevan Krogan's lab, San Francisco, CA
4St Louis Hospital, INSERM U944, PARIS, FRA
5Assistance Publique Des Hopitaux De Paris (AP-HP) - Universite Paris Descartes -, Paris, Ile-de-France, FRA
6APHP, Paris, FRA
7St Louis Hospital, AP-HP, PARIS, France
8Université De Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris,, Paris, FRA
9Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
10Department of Pharmacology and Cancer Biology, Kris Wood's lab, Durham, NC
11Institut de Recherche Saint-Louis (IRSL), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Paris Cité, Paris, France
12Pediatric Oncology, Dana-Farber Cancer Institute, Boston
13INSERM U944, Paris, FRA
14Cytomorpholab, PARIS, France
15Duke University School of Medicine, Durham, NC
16St Louis Hospital, INSERM U944, Paris, France
17Cochin Institute, PARIS, France
18Hematology department, Saint-Louis Hospital, Paris, France
19Institut de Recherche Saint-Louis, INSERM UMR 944, Paris, France
20Service d’Hématologie Clinique, Hôpital Saint-Louis, Paris, FRA
21Laboratoire d'Hématologie, Université Paris Cité, Assistance Publique des Hôpitaux de Paris Nord, Hôpital Saint-Louis, Paris, France
22Department of Pharmacology and Cancer Biology, Duke University, Durham, NC
23UMR7212/U944, Institut National de la Santé et de la Recherche Médicale, Saint-Louis Institute, University Paris 7, Paris, France
24INSERM U944, Saint-Louis Research Institute, Paris, France

9:45 AM

Li Du, PhD1,2,3, Jiamin Guo, MSc2,4, Zhenhua Chen, PhD5*, Jianjun Chen, PhD5, Guido Marcucci, MD6 and Steven T. Rosen, MD7,8

1Judy and Bernard Briskin Center for Multiple Myeloma Research, Beckman Research Institute City of Hope, Duarte, CA
2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
3Toni Stephenson Lymphoma Center, Beckman Research Institute City of Hope, Duarte, CA
4Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, Duarte, CA
5Department of Systems Biology, Beckman Research Institute, City of Hope, Monrovia, CA
6Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA
7Department of Hematology and HCT, City of Hope Comprehensive Cancer Center, Duarte, CA
8Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA

10:00 AM

Priyanka Sharma, PhD1, Lauren B. Ostermann, BSc1*, Sujan Piya, PhD1*, Baozhen Ke, BS1*, Natalia Baran, MD, PhD, MSc2, Anudishi Tyagi, PhD3*, Muharrem Muftuoglu, MD1, Mahesh Basyal, BSc4*, Qi Zhang, PhD3*, Joanne Munck, PhD5*, Kim-Hien Dao, DO, PhD6*, Martin Sims, PhD5*, Bing Z. Carter, PhD1, Venkata Lokesh Battula, PhD7, Michael Andreeff, MD PhD3 and Gautam Borthakur, MD3

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
5Astex Pharmaceuticals, Cambridge, United Kingdom
6Astex Pharmaceuticals, Inc., Pleasanton, CA
7Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX

10:15 AM

Kedwin Ventura, MS1*, Josh Prokopec2*, Biswas Neupane, PhD1*, Zhenxia Gao1*, Wei Du, MD1*, Yinan Gong, PhD2* and Sawa Ito, MD1

1Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
2Hillman Cancer Center/Department of Immunology, University of Pittsburgh, Pittsburgh, PA

10:30 AM

Satoshi Kaito, MD, PhD1*, Kazumasa Aoyama, PhD1*, Motohiko Oshima, PhD1*, Karl Agger, PhD2*, Kristian Helin, PhD2*, Yasuhito Nannya, MD, PhD3, Seishi Ogawa4, Atsuya Nishiyama, PhD5*, Makoto Nakanishi, MD, PhD5* and Atsushi Iwama, MD, PhD1

1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2BRIC, University of Copenhagen, Copenhagen, Denmark
3Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
4Department of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Sakyoku, KYO, Japan
5Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

10:45 AM

Zhixiang Chen, MD1,2*, Yuanhua Cai, MD, PhD1,2*, Xiaolin Lai, MD, PhD2*, Xuechun Wang, PhD3*, Xiongbin Yan, MD1,2*, Yaping Wang, MD, PhD1,2*, Fuquan Tu, MD, PhD2,4*, Wanting Wu, MD1,2*, Yang Li, MD, PhD1,2*, Lili Pan, MD, PhD2*, Yi Zheng, MD2*, Jinggang Li, MD, PhD2*, Xiaofan Li, MD, PhD1,2 and Shaoyuan Wang, MD1,2*

1Union Clinical Medical Colleges, Fujian Medical University, Fuzhou, China
2Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China
3Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, NJ, China
4Emergency Intensive Care Unit, Fujian Medical University Union Hospital, Fuzhou, China

*signifies non-member of ASH